Autologous insulin developer Orgenesis forms Israeli cell therapy JV

By Dan Stanton

- Last updated on GMT

Image: iStock/CountDuckula
Image: iStock/CountDuckula
Orgenesis and Atvio have formed a cell therapy contract manufacturing joint venture and are looking to procure a GMP facility in Israel.

Orgenesis is a Maryland-based biotech which is using its Autologous Insulin Producing (AIP) cell transplantation technology to develop a cell therapy for diabetes.

According to an SEC filing​, the firm has entered into a 50-50 joint venture with newly formed Israeli company Atvio Biotech in order to form a contract development and manufacturing organisation (CDMO) for cell and virus therapy products in the field of regenerative medicine within Israel.

While Orgenesis did not respond to Biopharma-Reporter.com for more information, the filing says the firm has paid Atvio has been charged with setting up and maintaining a GMP facility in Israel, and has received $1m from Orgenesis to cover the costs.

“[Orgenesis] will share with Atvio the Company’s know-how in the field of cell therapy manufacturing, which know-how will not include the intellectual property included in the license from the Tel Hashomer Hospital in Israel to Orgenesis Ltd., the Company’s subsidiary,”​ the filing added.

The company’s initial product takes a liver biopsy from the patient, sends it to a central laboratory where the manufacturing platform is used to produce a sufficient amount of AIP cells which are then transplanted back into a patient’s liver.

In March 2015​, the firm acquired contract manufacturer Masthercell SA to help progress the treatment into the clinic, adding a GMP production facility in Gosselies, Belgium.

If proven clinically successful, the firm claims the regeneration of functional insulin-producing cells could transform the diabetes treatment space.

Related news

Show more

Related suppliers

Follow us

Webinars

Follow us